Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Reviva Pharmaceuticals Holdings ( (RVPH) ) has shared an announcement.
On June 26, 2025, Reviva Pharmaceuticals Holdings, Inc. entered into agreements for a registered public offering, selling 20,000,000 shares of common stock and warrants for an aggregate of $10.0 million. The net proceeds of approximately $9.0 million will be used for research and development, working capital, and general corporate purposes. The offering is expected to close on June 27, 2025, subject to customary conditions, and includes restrictions on stock issuance for 60 days post-closing. This move is aimed at bolstering Reviva’s financial resources to advance its drug development pipeline.
The most recent analyst rating on (RVPH) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Reviva Pharmaceuticals Holdings stock, see the RVPH Stock Forecast page.
Spark’s Take on RVPH Stock
According to Spark, TipRanks’ AI Analyst, RVPH is a Underperform.
Reviva Pharmaceuticals Holdings faces significant financial challenges, with zero revenue, substantial net losses, and negative cash flows, heavily weighing down its stock score. The technical analysis indicates weak momentum and a downward trend, while the negative P/E ratio and lack of dividends reflect poor valuation. Recent corporate events show leadership confidence but do not mitigate the underlying financial distress.
To see Spark’s full report on RVPH stock, click here.
More about Reviva Pharmaceuticals Holdings
Reviva Pharmaceuticals Holdings, Inc. is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing next-generation therapeutics for diseases with unmet medical needs, particularly in the areas of central nervous system (CNS), inflammatory, and cardiometabolic diseases. Their pipeline includes drug candidates such as brilaroxazine (RP5063) and RP1208, with patents granted in the United States, Europe, and other countries.
Average Trading Volume: 686,951
Technical Sentiment Signal: Sell
Current Market Cap: $35.7M
For an in-depth examination of RVPH stock, go to TipRanks’ Overview page.